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In response to increased demands placed on biopharmaceutical manufacturers to diversify portfolios and to 
reduce costs, bioprocesses are being intensified to allow for significant protein production in ≤2,000L single-use 
bioreactors.  Many biopharmaceutical manufacturers are maturing continuous bioprocessing platforms to meet 
these demands.  Hardware, which was once thought to be novel and high-risk for failure, is now being proven as 
robust at-scale.  When coupled with single-use technology, these processes enable biomanufacturing facilities 
to be built faster at a lower cost, with more flexibility for reconfiguration and support of regional manufacturing.  
Many challenges remain to achieving this final vision including liquid management for large-scale perfusion 
operations, overcoming product sieving decay often encountered in filtration-based cell retention devices, and 
bioburden control for long duration operations.   
 
In a collaborative case study, Merck & Co., Inc. and Just Biotherapeutics will demonstrate a strategy leveraging 
fully single-use equipment and connected operations for an extended duration at manufacturing-scale (500L).  
This presentation will highlight bioreactor performance with the deployment of media concentrate technology to 
ease the logistical, staffing and space constraints of a traditional perfusion process, as well as implementation of 
large-scale microfiltration membranes for cell retention with consistently high protein transmission.  In addition, 
data will be presented not only on the performance of a linked continuous multi-column protein A 
chromatography capture step, but also bioburden monitoring from multiple points in the process.  Advancements 
implemented during this campaign as well as valuable lessons learned will open the door to further expanding 
the continuous boundary of connected operations and continuous bioprocessing. 
 
